A 5-year summary of real-life dietary egg consumption after completion of a 4-year egg powder oral immunotherapy (eOIT) protocol

Edwin H. Kim; Stacie M. Jones; A. Wesley Burks; Robert A. Wood; Scott H. Sicherer; Donald Y.M. Leung; Alice K. Henning; Robert W. Lindblad; Peter Dawson; Corinne Keet; Amy M. Scurlock; Marshall Plaut; Hugh A. Sampson

doi:10.1016/j.jaci.2019.11.045

A 5-year summary of real-life dietary egg consumption after completion of a 4-year egg powder oral immunotherapy (eOIT) protocol

Edwin H. Kim, Stacie M. Jones, A. Wesley Burks, Robert A. Wood, Scott H. Sicherer, Donald Y.M. Leung, Alice K. Henning, Robert W. Lindblad, Peter Dawson, Corinne Keet, Amy M. Scurlock, Marshall Plaut, Hugh A. Sampson

School of Medicine

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Original language	English (US)
Pages (from-to)	1292-1295.e1
Journal	Journal of Allergy and Clinical Immunology
Volume	145
Issue number	4
DOIs	https://doi.org/10.1016/j.jaci.2019.11.045
State	Published - Apr 2020

ASJC Scopus subject areas

Immunology and Allergy
Immunology

Access to Document

10.1016/j.jaci.2019.11.045

Cite this

Kim, E. H., Jones, S. M., Burks, A. W., Wood, R. A., Sicherer, S. H., Leung, D. Y. M., Henning, A. K., Lindblad, R. W., Dawson, P., Keet, C., Scurlock, A. M., Plaut, M., & Sampson, H. A. (2020). A 5-year summary of real-life dietary egg consumption after completion of a 4-year egg powder oral immunotherapy (eOIT) protocol. Journal of Allergy and Clinical Immunology, 145(4), 1292-1295.e1. https://doi.org/10.1016/j.jaci.2019.11.045

Kim, EH, Jones, SM, Burks, AW, Wood, RA, Sicherer, SH, Leung, DYM, Henning, AK, Lindblad, RW, Dawson, P, Keet, C, Scurlock, AM, Plaut, M & Sampson, HA 2020, 'A 5-year summary of real-life dietary egg consumption after completion of a 4-year egg powder oral immunotherapy (eOIT) protocol', Journal of Allergy and Clinical Immunology, vol. 145, no. 4, pp. 1292-1295.e1. https://doi.org/10.1016/j.jaci.2019.11.045

@article{fa6dadb01b7b40eda914fe3ff8d6e503,

title = "A 5-year summary of real-life dietary egg consumption after completion of a 4-year egg powder oral immunotherapy (eOIT) protocol",

author = "Kim, {Edwin H.} and Jones, {Stacie M.} and Burks, {A. Wesley} and Wood, {Robert A.} and Sicherer, {Scott H.} and Leung, {Donald Y.M.} and Henning, {Alice K.} and Lindblad, {Robert W.} and Peter Dawson and Corinne Keet and Scurlock, {Amy M.} and Marshall Plaut and Sampson, {Hugh A.}",

note = "Funding Information: Disclosure of potential conflict of interest: E. H. Kim reports consultancy with Aimmune Therapeutics, DBV Technologies, AllerGenis, and Allakos; clinical medical advisory board membership with DBV Technologies; and grant funding from the National Institutes of Health (NIH)-NIAID, NIH–National Center for Complementary and Integrative Health, Food Allergy Research and Education (FARE), and the Wallace Research Foundation. S. M. Jones is on the research advisory board for FARE; has consultant arrangements with Aimmune Therapeutics and Astellas Pharma Global Development, Inc; has received grants from Aimmune Therapeutics, DBV Technologies, Astellas, Regeneron, Genentech, FARE, the NIH/NIAID Immune Tolerance Network, and the NIH/NIAID Consortium for Food Allergy Research; and has performed Center for Scientific Review review/preparation for DBV Technologies on behalf of Emmes. A. W. Burks reports minority stock ownership in Allertein and Mast Cell Pharmaceuticals; advisory board membership with Aimmune Therapeutics, Consortia TX Inc, and Prota Therapeutics; consultancy for DBV Technologies, and N-fold; royalties from UpToDate; speaking fees from Gordon Research Conferences and Pediatric Allergy and Asthma Meetings; and sponsored research with FARE and the NIH. R. A. Wood reports royalty payments from UpToDate and grants to his institution from the NIAID, Aimmune Therapeutics, DBV, Astellas, Sanofi, and HAL Allergy Group. S. H. Sicherer reports grants from the NIAID during conduct of the study; personal fees from the American Academy of Allergy, Asthma & Immunology; and personal fees from UpToDate and Johns Hopkins University Press outside the submitted work. D. Y. M. Leung receives grant support to his institution from the NIAID and National Institute of Arthritis and Musculoskeletal and Skin Diseases and is chairman of the data and safety and monitoring committee for Aimmune. A. K. Henning is employed by Emmes, which received support for this work via a grant from the Division of Allergy, Immunology, and Transplantation (DAIT)/NIAID/NIH through Johns Hopkins University. R. W. Lindblad is employed by Emmes, which received support for this work via grant from DAIT/NIAID/NIH through Johns Hopkins University. P Dawson is employed by Emmes, which received support for this work via a grant from the DAIT/NIAID/NIH through Johns Hopkins University. C. Keet reports grant funding from the NIH, royalties from Up-To-Date, and membership on the board of the American Board of Allergy and Immunology. A. M. Scurlock reports membership on the DBV Clinical Medical Advisory Board and FARE Clinical Network and has received NIH/NIAID funding, as well as clinical trials funding from Aimmune, Astellas, DBV, Regeneron. H. A. Sampson reports being a part-time employee of DBV Technologies, receiving consultant fees from N-Fold LLC and royalties for various textbooks, holding stock options in DBV Technologies and N-FOLD, and receiving grants from the NIH/NIAID. M. Plaut declares no relevant conflicts of interest. Funding Information: Supported by the National Institutes of Health (NIH)?National Institute of Allergy and Infectious Diseases (NIAID) (grants U19AI066738 and U01AI066560). The project was also supported by grants UL1 RR-025780 (University of Colorado Denver), UL1 TR-000067 (Icahn School of Medicine at Mount Sinai), UL1 TR-000039 (University of Arkansas for Medical Sciences), UL1 TR-000083 (University of North Carolina at Chapel Hill), and UL1 TR-000424 (Johns Hopkins University) from the National Center for Research Resources (a component of the NIH). Its contents are solely the responsibility of the authors and do not necessarily represent the official view of the National Center for Research Resources or the NIH. Disclosure of potential conflict of interest: E. H. Kim reports consultancy with Aimmune Therapeutics, DBV Technologies, AllerGenis, and Allakos; clinical medical advisory board membership with DBV Technologies; and grant funding from the National Institutes of Health (NIH)-NIAID, NIH?National Center for Complementary and Integrative Health, Food Allergy Research and Education (FARE), and the Wallace Research Foundation. S. M. Jones is on the research advisory board for FARE; has consultant arrangements with Aimmune Therapeutics and Astellas Pharma Global Development, Inc; has received grants from Aimmune Therapeutics, DBV Technologies, Astellas, Regeneron, Genentech, FARE, the NIH/NIAID Immune Tolerance Network, and the NIH/NIAID Consortium for Food Allergy Research; and has performed Center for Scientific Review review/preparation for DBV Technologies on behalf of Emmes. A. W. Burks reports minority stock ownership in Allertein and Mast Cell Pharmaceuticals; advisory board membership with Aimmune Therapeutics, Consortia TX Inc, and Prota Therapeutics; consultancy for DBV Technologies, and N-fold; royalties from UpToDate; speaking fees from Gordon Research Conferences and Pediatric Allergy and Asthma Meetings; and sponsored research with FARE and the NIH. R. A. Wood reports royalty payments from UpToDate and grants to his institution from the NIAID, Aimmune Therapeutics, DBV, Astellas, Sanofi, and HAL Allergy Group. S. H. Sicherer reports grants from the NIAID during conduct of the study; personal fees from the American Academy of Allergy, Asthma & Immunology; and personal fees from UpToDate and Johns Hopkins University Press outside the submitted work. D. Y. M. Leung receives grant support to his institution from the NIAID and National Institute of Arthritis and Musculoskeletal and Skin Diseases and is chairman of the data and safety and monitoring committee for Aimmune. A. K. Henning is employed by Emmes, which received support for this work via a grant from the Division of Allergy, Immunology, and Transplantation (DAIT)/NIAID/NIH through Johns Hopkins University. R. W. Lindblad is employed by Emmes, which received support for this work via grant from DAIT/NIAID/NIH through Johns Hopkins University. P Dawson is employed by Emmes, which received support for this work via a grant from the DAIT/NIAID/NIH through Johns Hopkins University. C. Keet reports grant funding from the NIH, royalties from Up-To-Date, and membership on the board of the American Board of Allergy and Immunology. A. M. Scurlock reports membership on the DBV Clinical Medical Advisory Board and FARE Clinical Network and has received NIH/NIAID funding, as well as clinical trials funding from Aimmune, Astellas, DBV, Regeneron. H. A. Sampson reports being a part-time employee of DBV Technologies, receiving consultant fees from N-Fold LLC and royalties for various textbooks, holding stock options in DBV Technologies and N-FOLD, and receiving grants from the NIH/NIAID. M. Plaut declares no relevant conflicts of interest. Funding Information: Supported by the National Institutes of Health (NIH)– National Institute of Allergy and Infectious Diseases (NIAID) (grants U19AI066738 and U01AI066560 ). The project was also supported by grants UL1 RR-025780 ( University of Colorado Denver ), UL1 TR-000067 (Icahn School of Medicine at Mount Sinai ), UL1 TR-000039 ( University of Arkansas for Medical Sciences ), UL1 TR-000083 ( University of North Carolina at Chapel Hill ), and UL1 TR-000424 (Johns Hopkins University) from the National Center for Research Resources (a component of the NIH). Its contents are solely the responsibility of the authors and do not necessarily represent the official view of the National Center for Research Resources or the NIH. ",

year = "2020",

month = apr,

doi = "10.1016/j.jaci.2019.11.045",

language = "English (US)",

volume = "145",

pages = "1292--1295.e1",

journal = "Journal of Allergy and Clinical Immunology",

issn = "0091-6749",

publisher = "Mosby Inc.",

number = "4",

}

TY - JOUR

T1 - A 5-year summary of real-life dietary egg consumption after completion of a 4-year egg powder oral immunotherapy (eOIT) protocol

AU - Kim, Edwin H.

AU - Jones, Stacie M.

AU - Burks, A. Wesley

AU - Wood, Robert A.

AU - Sicherer, Scott H.

AU - Leung, Donald Y.M.

AU - Henning, Alice K.

AU - Lindblad, Robert W.

AU - Dawson, Peter

AU - Keet, Corinne

AU - Scurlock, Amy M.

AU - Plaut, Marshall

AU - Sampson, Hugh A.

N1 - Funding Information: Disclosure of potential conflict of interest: E. H. Kim reports consultancy with Aimmune Therapeutics, DBV Technologies, AllerGenis, and Allakos; clinical medical advisory board membership with DBV Technologies; and grant funding from the National Institutes of Health (NIH)-NIAID, NIH–National Center for Complementary and Integrative Health, Food Allergy Research and Education (FARE), and the Wallace Research Foundation. S. M. Jones is on the research advisory board for FARE; has consultant arrangements with Aimmune Therapeutics and Astellas Pharma Global Development, Inc; has received grants from Aimmune Therapeutics, DBV Technologies, Astellas, Regeneron, Genentech, FARE, the NIH/NIAID Immune Tolerance Network, and the NIH/NIAID Consortium for Food Allergy Research; and has performed Center for Scientific Review review/preparation for DBV Technologies on behalf of Emmes. A. W. Burks reports minority stock ownership in Allertein and Mast Cell Pharmaceuticals; advisory board membership with Aimmune Therapeutics, Consortia TX Inc, and Prota Therapeutics; consultancy for DBV Technologies, and N-fold; royalties from UpToDate; speaking fees from Gordon Research Conferences and Pediatric Allergy and Asthma Meetings; and sponsored research with FARE and the NIH. R. A. Wood reports royalty payments from UpToDate and grants to his institution from the NIAID, Aimmune Therapeutics, DBV, Astellas, Sanofi, and HAL Allergy Group. S. H. Sicherer reports grants from the NIAID during conduct of the study; personal fees from the American Academy of Allergy, Asthma & Immunology; and personal fees from UpToDate and Johns Hopkins University Press outside the submitted work. D. Y. M. Leung receives grant support to his institution from the NIAID and National Institute of Arthritis and Musculoskeletal and Skin Diseases and is chairman of the data and safety and monitoring committee for Aimmune. A. K. Henning is employed by Emmes, which received support for this work via a grant from the Division of Allergy, Immunology, and Transplantation (DAIT)/NIAID/NIH through Johns Hopkins University. R. W. Lindblad is employed by Emmes, which received support for this work via grant from DAIT/NIAID/NIH through Johns Hopkins University. P Dawson is employed by Emmes, which received support for this work via a grant from the DAIT/NIAID/NIH through Johns Hopkins University. C. Keet reports grant funding from the NIH, royalties from Up-To-Date, and membership on the board of the American Board of Allergy and Immunology. A. M. Scurlock reports membership on the DBV Clinical Medical Advisory Board and FARE Clinical Network and has received NIH/NIAID funding, as well as clinical trials funding from Aimmune, Astellas, DBV, Regeneron. H. A. Sampson reports being a part-time employee of DBV Technologies, receiving consultant fees from N-Fold LLC and royalties for various textbooks, holding stock options in DBV Technologies and N-FOLD, and receiving grants from the NIH/NIAID. M. Plaut declares no relevant conflicts of interest. Funding Information: Supported by the National Institutes of Health (NIH)?National Institute of Allergy and Infectious Diseases (NIAID) (grants U19AI066738 and U01AI066560). The project was also supported by grants UL1 RR-025780 (University of Colorado Denver), UL1 TR-000067 (Icahn School of Medicine at Mount Sinai), UL1 TR-000039 (University of Arkansas for Medical Sciences), UL1 TR-000083 (University of North Carolina at Chapel Hill), and UL1 TR-000424 (Johns Hopkins University) from the National Center for Research Resources (a component of the NIH). Its contents are solely the responsibility of the authors and do not necessarily represent the official view of the National Center for Research Resources or the NIH. Disclosure of potential conflict of interest: E. H. Kim reports consultancy with Aimmune Therapeutics, DBV Technologies, AllerGenis, and Allakos; clinical medical advisory board membership with DBV Technologies; and grant funding from the National Institutes of Health (NIH)-NIAID, NIH?National Center for Complementary and Integrative Health, Food Allergy Research and Education (FARE), and the Wallace Research Foundation. S. M. Jones is on the research advisory board for FARE; has consultant arrangements with Aimmune Therapeutics and Astellas Pharma Global Development, Inc; has received grants from Aimmune Therapeutics, DBV Technologies, Astellas, Regeneron, Genentech, FARE, the NIH/NIAID Immune Tolerance Network, and the NIH/NIAID Consortium for Food Allergy Research; and has performed Center for Scientific Review review/preparation for DBV Technologies on behalf of Emmes. A. W. Burks reports minority stock ownership in Allertein and Mast Cell Pharmaceuticals; advisory board membership with Aimmune Therapeutics, Consortia TX Inc, and Prota Therapeutics; consultancy for DBV Technologies, and N-fold; royalties from UpToDate; speaking fees from Gordon Research Conferences and Pediatric Allergy and Asthma Meetings; and sponsored research with FARE and the NIH. R. A. Wood reports royalty payments from UpToDate and grants to his institution from the NIAID, Aimmune Therapeutics, DBV, Astellas, Sanofi, and HAL Allergy Group. S. H. Sicherer reports grants from the NIAID during conduct of the study; personal fees from the American Academy of Allergy, Asthma & Immunology; and personal fees from UpToDate and Johns Hopkins University Press outside the submitted work. D. Y. M. Leung receives grant support to his institution from the NIAID and National Institute of Arthritis and Musculoskeletal and Skin Diseases and is chairman of the data and safety and monitoring committee for Aimmune. A. K. Henning is employed by Emmes, which received support for this work via a grant from the Division of Allergy, Immunology, and Transplantation (DAIT)/NIAID/NIH through Johns Hopkins University. R. W. Lindblad is employed by Emmes, which received support for this work via grant from DAIT/NIAID/NIH through Johns Hopkins University. P Dawson is employed by Emmes, which received support for this work via a grant from the DAIT/NIAID/NIH through Johns Hopkins University. C. Keet reports grant funding from the NIH, royalties from Up-To-Date, and membership on the board of the American Board of Allergy and Immunology. A. M. Scurlock reports membership on the DBV Clinical Medical Advisory Board and FARE Clinical Network and has received NIH/NIAID funding, as well as clinical trials funding from Aimmune, Astellas, DBV, Regeneron. H. A. Sampson reports being a part-time employee of DBV Technologies, receiving consultant fees from N-Fold LLC and royalties for various textbooks, holding stock options in DBV Technologies and N-FOLD, and receiving grants from the NIH/NIAID. M. Plaut declares no relevant conflicts of interest. Funding Information: Supported by the National Institutes of Health (NIH)– National Institute of Allergy and Infectious Diseases (NIAID) (grants U19AI066738 and U01AI066560 ). The project was also supported by grants UL1 RR-025780 ( University of Colorado Denver ), UL1 TR-000067 (Icahn School of Medicine at Mount Sinai ), UL1 TR-000039 ( University of Arkansas for Medical Sciences ), UL1 TR-000083 ( University of North Carolina at Chapel Hill ), and UL1 TR-000424 (Johns Hopkins University) from the National Center for Research Resources (a component of the NIH). Its contents are solely the responsibility of the authors and do not necessarily represent the official view of the National Center for Research Resources or the NIH.

PY - 2020/4

Y1 - 2020/4

UR - http://www.scopus.com/inward/record.url?scp=85078182573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85078182573&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2019.11.045

DO - 10.1016/j.jaci.2019.11.045

M3 - Article

C2 - 31881232

AN - SCOPUS:85078182573

SN - 0091-6749

VL - 145

SP - 1292-1295.e1

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

IS - 4

ER -

A 5-year summary of real-life dietary egg consumption after completion of a 4-year egg powder oral immunotherapy (eOIT) protocol

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this